Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 19, 2021

Oregon Oncology to integrate Deep Lens’ clinical trial platform

Oregon Oncology Specialists has signed a strategic collaboration to integrate a Deep Lens’ artificial-intelligence (AI)-based clinical trial screening platform to expand patient access to clinical trials.

Oregon Oncology Specialists has signed a strategic collaboration to integrate a Deep Lens’ artificial-intelligence (AI)-based clinical trial screening platform to expand patient access to clinical trials.

Under the partnership, Oregon Oncology will integrate VIPER into its community oncology practice network.

The platform will be integrated directly to Oregon Oncology Specialists EMR (iKnowMed), molecular data feeds (Guardant Health and Foundation Medicine), and pathology feeds for the automatic identification of qualified patients for clinical trials.

Using Cloud-based technology, VIPER can facilitate, triage and accelerate the clinical trial recruitment process. The technology will ensure identification of eligible patients quickly in the clinical trial enrolment process.

Oregon Oncology Specialists research medical director Janelle Meyer said: “Recent innovations in the development of cancer therapies have largely been guided by the increase in knowledge about the way specific tumour types manifest themselves in different people based on unique genetic characteristics.

“We are confident that the integration of VIPER will not only help strengthen our clinical trial offerings to patients, but it will also ensure that we are matching patients in real-time to trials for which they are appropriate.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Estimates show that more than 15,000 oncology clinical trials are actively recruiting patients, however, their participation is often as low as 3%.

Deep Lens chief revenue officer Greg Andreola said: “The staff at Oregon Oncology Specialists has an excellent track record of adopting the newest, most current technologies and treatment options for their patient community.

“VIPER’s automated and comprehensive ‘matchmaking’ process will significantly expand the clinical trial programme for Oregon patients and ensure that the right patients are being matched to the right trials in real-time, based on their specific diagnosis and needs.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU